An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously

Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment

(2021) Sun Yoo et al.   Clinical Gastroenterology and Hepatology

Systemic treatment of hepatocellular carcinoma: An EASL position paper

(2021) Jordi Bruix et al.   JOURNAL OF HEPATOLOGY

Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer

(2020) Dan Pu et al.   MEDICINE

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma

(2020) Pei-Chang Lee et al.   Journal for ImmunoTherapy of Cancer

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

(2018) Norah A. Terrault et al.   HEPATOLOGY

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(2018) Andrew X Zhu et al.   LANCET ONCOLOGY

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

(2017) Pietro Lampertico et al.   JOURNAL OF HEPATOLOGY

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET